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Value of Holter Monitoring in Predicting Long-Term Efficacy and
Inefficacy of Amiodarone Used Alone and in Combination With Class
lA Antiarrhythmic Agents in Patients With Ventricular Tachycardia
500 G. KIM, MD, FACC, SAMUEL D. FELDER, MD, ILONA FIGURA, MD,
DEBRA R. JOHNSTON, RN, LAWRENCE E. WASPE, MD, FACC, JOHN D. FISHER, MD, FACC
Bronx , New York
The value of two reported and two new ambulatory
electrocardiographic (Holter) criteria was studied in 80
patients taking amiodarone for refractory recurrent sus-
tained ventricular tachycardia. In the 80 patients, the
four Holter criteria were as follows: 1-85% or greater
reduction of ventricular premature complexes and ab-
olition of couplets and nonsustained ventricular tachy-
cardia in 74 patients who had 10 or more ventricular
preniature complexes/h, or any couplets or nonsustained
ventricular tachycardia/24 hours at baseline; II-abo-
lition of nonsustained ventricular tachycardia in 51 pa-
tients who had nonsustained ventricular tachycardia at
baseline; 111-85% or greater reduction of ventricular
premature complexes and abolition of nonsustained ven-
tricular tachycardia in 64 patients who had 30 or more
ventricular premature complexes/h at baseline; and IV-
85% or greater reduction of ventricular premature com-
plexes and abolition of nonsustained ventricular tachy-
cardia in 73 patients who had 10 or more ventricular
premature complexes/h at baseline. Amiodarone was
judged effective in, respectively, 51 of 74, 44 of 51, 51
of 64 and 61 of 73 patients by criterion I, II, III or IV.
During the follow-up period (19 ± 20 months), there
were 19 instances of recurrence of ventricular arrhyth-
The role of ambulatory electrocardiographic (Holter) mon-
itoring in assessing the efficac y of amiodarone therap y in
patient s with ventricular tachyc ardias is still controversial.
Some investigators (1-3) have reported good predictive val-
ues of Holter monitoring; others (4, 5) have reported poor
values. These reported differences may bedue to differences
in patient groups and efficacy criteria in the various studies
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mia or sudden death. Actuarial arrhythmia-free survival
rate at 24 months was 84,74,86 and 85%, respectively,
in patients with efficacy by criterion I, II, III or IV and
61,43,48 and 39%, respectively, in patients with inef-
ficacy (p < 0.015 for all). Many patients with efficacy
by Holter criteria, however, had a recurrence of ar-
rhythmia, suggesting insensitivity of these Holter crite-
ria. At 24 months, the respective sensitivity of criteria
I, II, III and IV was 53, 29, 50 and 47%, the specificity
was 86,94,90 and 95% and the predictive accuracy was
73, 63, 75 and 76%.
Conclusions: I) Inefficacy of amiodarone therapy by
Holter criteria predicts a poor outcome but efficacy does
not preclude a poor outcome (insensitivity). 2) Criterion
I is the most sensitive but the least specific. 3) Criterion
II could be used in only 51 of 80 patients and is the least
sensitive. 4) Criterion III (with a stricter entry criterion)
could be used in fewer patients than criterion I or IV
and accuracy is not better. 5) Criterion IV is the most
specificand has the best predictive accuracy. 6) Further
studies should be done to identify the predictor of ar-
rhythmia recurrence in patients with Holter criteria of
efficacy.
(J Am Coil CardioI1987;9:169-74)
(1-5) . To determine the value of Holter monitoring and to
compare the accuracies of variou s efficacy criteria reported
to be predictive, we used serial Holter monitoring at baseline
and during amiodarone therap y in 80 patients with refractory
ventricular tachycardia or ventricular fibrillation taking
amiodarone. From the results of follow-up of these patient s.
the predictive values of two reported Holter efficacy criteria
and two new criteria were evaluated .
Methods
Study patients. Eighty patients (63 male, 17 female;
mean age 61 ± 10 years) with recurrent sustained ventric-
ular tachycardia with hemodynamic compromise (76 pa-
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tients) or ventricular fibrillation (4 patients) refractory to
conventional antiarrhythmic agents and mexiletine were
studied. Sixty patients had coronary artery disease and 20
had cardiomyopathy. None of the arrhythmias were asso-
ciated with acute myocardial infarction or remediable causes
(such as hypokalemia, digitalis toxicity or drug-induced ar-
rhythmia) . Patients with arrhythmias refractory to conven-
tiona l nonexperimental drugs and mexiletine or with intol-
erable side effects from conventional drugs and mexiletine
were entered into this study.
Ambulatory electrocardiographic monitoring. The
detailed methods have been published (6). Continuous 24
hour ambulatory electrocardiograms were recorded on an
Avionics" 445 two-channel recorder. Analysis of the tape
was done on a computerized Cardio Data System" scanner.
Total numbers of ventricular premature complexes, couplets
and nonsustained ventricular tachycardia (:2:3 ventricular
premature complexes at a rate of :2: 100 beats/min) were
generated by the scanner. Accuracy of the system has been
previously validated (6). The accuracy of the count of total
ventricular premature complexes was 96.3 ± 3.7%, of cou-
plets 93 .7 ± 6.7% and of ventricular tachycardia 96.2 ±
5.8%. The results were verified by three of the investigators
(S.K., L.W. , J.F.). Mean ventricular premature com-
plexes/h or couplets/h were calculated by dividing total num-
ber of ventricular premature complexes or couplets by the
number of hours recorded.
Efficacy criteria by ambulatory monitoring. For this
study, four Holter efficacy criteria were used (Table I) . By
Holter efficacy criterion I, amiodarone was considered ef-
fective when it resulted in 85% or greater reduction of ven-
tricular premature complexes and abolition of couplets and
nonsustained ventricular tachycardia in patients who had 10
or more ventricular premature complexes/hour or any cou-
plets or nonsustained ventricular tachycardia/24 h on Holter
monitoring at baseline (1). By criterion II, amiodarone was
considered effective when it resulted in abolition of non-
sustained ventricular tachycardias in patients who had non-
sustained ventricular tachycardias at baseline (2). By cri-
terion III, amiodarone was considered effective when it
resulted in 85% or greater reduction of ventricular premature
complexes (1,7) and abolition of nonsustained ventricuiar
tachycardia (2,8) in patients who had 30 or more ventricular
premature complexes/h at baseline (7,9-12) . By criterion
IV, amiodarone was considered effecti ve when it resulted
in 85% or greater reduction of ventricular premature com-
plexes (1,7) and abolition of nonsustained ventricular tachy-
cardia (2,8) in patients who had 10 or more ventricular
premature complexes at baseline (I) .
Study design. Informed consent was obtained from all
patients for the monitoring study and administration of amio-
darone. All patients had a baseline 24 hour ambulatory
electrocardiogram at least 5 half-lives after discontinuation
of all antiarrhythmic medications. Amiodarone was given
orally twice daily in equally divided doses. All patients
received a loading dose of amiodarone (939 ± 281 mg/day)
for 16 ± 7 days followed by a maintenance dose of
360 ± 112 rng/day. An additional class IA antiarrhythmic
agent was given in 19 patients . Holter monitoring was re-
peated and the efficacy of amiodarone was assessed by Hol-
ter criteria in all patients before discharge from the hospital.
All patients were discharged on treatment with amiodarone
and followed up by the arrhythmia service of this institution .
The end point of follow-up was I) recurrence of sustained
ventricular tachycardia or sudden death ; 2) other death; 3)
discontinuation of the discharge regimen due to side effects;
or 4) arrhythmia-free survival as of February 15, 1986.
Statistical methods. Standard deviation (mean ± SO)
was used as the index of dispersion of observed values .
Kaplan-Meier's method was used to generate actuarial sur-
vival rates of each group. The differences between groups
were tested by log-rank test for statistical significance. A
two-tailed probability value of less than 0.05 was considered
significant. The sensitivity, specificity, positive predictive
value, negative predictive value and predictive accuracy
were defined as follows: sensitivity = TP/(TP + FN),
specificity = TN/(TN + FP), positive predictive value
TP/(TP + FP), negative predictive value = TN/(TN +
Table 1. Holter Monitoring Efficacy Criteria. Table 2. Results of Holter Monitoring at Baseline
Entry Criteria by No . of
Holter Baseline Holter Group Definition Patients
Criterion Monitorings Efficacy Criteria 2:30 VPCslh 64
2: 10 VPCslh , or any 2:85 % reduction of VPCs and IA With NSVT 48
couplets124 h or abolition of couplets and IB Without NSVT 16
NSVT124 h NSVT II ' < 30 but 2: 10 VPCs/h 9
II NSVT/24 h Abolition of NSVT IIA With NSVT 3
III 2:30 VPClh 2:85 % reduction of VPCs and lIB Without NSVT 6
abolition of NSVT III < 10 VPCs/h 7
IV 2: 10 VPC/h 2:85 % reduction of VPCs and IlIA With NSVT 0
abolition of NSVT IIIB Without NSVT but with couplets I
mc Without NSVT or couplets 6
NSVT = nonsustained ventricular tachycardia; VPCs = ventricular
premature complexes. Abbreviations as in Table I .
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Data are expressed as mean value :t SO in 80 patients . Abbreviations
as in Table I .
Table 3. Results of Holter Monitoring at Basel ine and During
Amiodarone Therapy.
p' 0.0140 by logrank test
VPCs/h
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Figure 2. Arrhythmia-free survival rates by Holter efficacy cri-
terion II (51 patients).
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Figure 1. Arrhythmia-free survival rates by Holter efficacy cri-
terion I (74 patients) .
tachycardiawere markedlyreducedcompared with the base-
line values (p < 0.00 I: ventricular prerriature complexes;
p < 0.001: couplets; and p < 0.025: nonsustained ventric-
ular tachycardias) (Table 3). Results of efficacyassessments
by various Holter efficacy criteria in individual patients are
shown in Table 4.
Results of follow-up. The mean duration of follow-up
was 18.6 ± 19.5 (SE = 2.4) months in all. There were
19 recurrences of arrhythmia or sudden deaths, 12 nonar-
rhythmic cardiac deaths and 4 deaths of noncardiac origin
during the entire follow-up period. Twelve patients had a
recurrence within 6 months after discharge and 15 patients
had a recurrence within 12 months. No patients had a re-
currence during the period between 12 and 24 months.
From the results of follow-up , actuarial arrhythmia-free
survival rates werealsogenerated by theKaplan-Meier method
and the differences between patients with efficacy and inef-
ficacy by each criterion were tested by the log rank test for
statistical significance (Fig. I to 4). The results are also
Patients (no.) II III IV
With amiodarone efficacy 51 44 51 61
With amiodarone inefficacy 23 7 13 12
Total 74 51 64 73
Holter Criterion
Table 4. Assessment of Amiodarone Efficacy
by Various Holter Criteria
Results
Holter monitoring at baseline. At baselinebeforeamio-
darone therapy, 64 (80%) of the 80 patients had 30 or more
ventricular premature cornplexes/h (group I), 9 (11%) had
less than 30 but 10 or more ventricular premature com-
plexes/h (group 2) and 7 (9%) had fewer than 10ventricular
premature complexes (group 3). Each group was further
subdivided by the presence (A) or absence (B) of nonsus-
tained ventricular tachycardia or couplets (Table 2). By
Holter criterion I, 74 of 80 patients (93%) (groups 1, 2, 3A
and 3B) qualified for the assessment by Holter monitoring.
By Holter criterion II, 51 patients (64%) (groups ~A ,. 2A
and 3A) qualified for the assessment by Holter momtonng.
By Holter criterion III, 64 patients (80%) (group I) qualified
for the assessmentby Holter monitoring. By Holtercriterion
IV, 73 patients (91%) (groups I and 2) qualified for the
assessment by Holter monitoring. Mean ventricular pre-
mature complex/h, couplets/h and number of episodes of
nonsustained ventricular tachycardia/24 h are shown in Ta-
ble 3.
Holter monitoring on amiodarone therapy. After
amiodarone therapy, mean frequencies of ventricular pre-
mature complexes, couplets and nonsustained ventricular
FN) and predictiveaccuracy = (TP + TN)/total population.
where TP = true positive (patients with inefficacy of amio-
darone therapy by the Holter criteria and subsequent clinical
arrhythmic events), TN = true negative (patients with ef-
ficacy by the Holter criteria and no clinical arrhythmic events),
FP = false positive (patients with inefficacy by the Holter
criteria but no clinical arrhythmic event) and FN = false
negative (patients with efficacy by the Holter criteria but
with subsequent clinical arrhythmic events).
172 KIM ET AL.
HOLTER MONITORING AND AMIODARONE EFFICACY
JACC Vol. 9. No.1
January 1987:169-74
Discussion
p·O.OOOO by logrank te.t
12
Duration of Follow-up (months)
0--0 Efficacy by Holter Ill:
f>.--6 Inefficacy by Holter Ill:
I
I
I
I
I
IIh
I
lr-,
I
!.---,
I
/",
I
~---------------------,
I
I
I
I
I
I
I
20
10
OL.------.l------::l---"'---~
tricular premature complexes/h. They suggested that in pa-
tients with less frequent «30/h) ventricular premature com-
plexes, even more marked reduction will be necessary to
attribute the reduction to a drug effect. Others have also
suggested that 30 or more ventricular premature com-
plexes/h may be necessary for reliable Holter assessment
(10-12). These observations form the basis of Holter cri-
terion III (9,13). Holter criterion IV was derived from cri-
teria I, II and III. Holter criteria III and IV were never
previously tested in patients taking amiodarone.
Data analysis and statistical methods. Different sta-
tistical methods were used in different studies cited in this
report (1,2,4,5), making it difficult to compare the results
of various studies. The value of the statistical methods used
in some of these studies has also been questioned (14).
Sensitivity, specificity and predictive accuracy obtained from
results during the entire follow-up period may not be val-
uable because there is no control for duration of follow-up
(14). To avoid the problems, We analyzed our data by sev-
eral statistical methods used by others (1,2,4,5) and com-
pared the values of various Holter monitoring criteria by
each statistical method. We also determined sensitivity,
specificity and predictive accuracy at 6, 12, 24 and 36 months
as has been suggested (14).
Qualification rates of various criteria. The "qualifi-
cation rates" (defined as the proportion of patients who are
qualified for the efficacy assessment by various criteria) of
Holter criteria I, II, III and IV were 93, 64, 80 and 91%,
respectively. In a significant number of patients, Holter
criterion II or III cannot be used to assess efficacy.
Accuracy ofvarious criteria. Actuarial arrhythmia-free
survival rates were significantly different between patients
with amiodarone efficacy and inefficacy by each criterion
used in this study. A significant number of patients with
amiodarone efficacy by each Holter criterion, however, had
a recurrence because of the insensitivity of each criterion.
The sensitivity of Holter criterion I was the highest, but
Figure 4. Arrhythmia-free survival rates by Holter efficacy cri-
terion IV (73 patients).
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summarized in Table 5. From the results of follow-up, sen-
sitivity, specificity, positive predictive value, negative pre-
dictive value and predictive accuracy of each criterion were
also generated and are shown in Tables 6 and 7.
The sensitivity of Holter criteria I, II, III and IV at 12
months were 53, 29, 50 and 47%, respectively. Holter cri-
terion II had the lowest sensitivity. A more stringent entry
criterion (criterion III) (2::30 ventricular premature com-
plexes/h at baseline instead of 2:: 10 ventricular premature
complexes/h) did not improve sensitivity and the number
of patients with false negative results (false efficacy) was
similar to those by criterion I or IV. The specificity of Holter
criteria I, II, III and IV at 12 months was 81, 87, 88 and
92%, respectively. Criterion I had the lowest and criterion
IV the highest specificity. The negative predictive value at
12 months was the lowest by criterion II and the positive
predictive value at 12 months was the lowest by criterion
I. At 12 months, the predictive accuracy of criterion IV was
the highest and that of criterion II was the lowest.
This study suggests that in patients with recurrent re-
fractory ventricular tachycardia taking amiodarone, alone
or in combination with a class lA antiarrhythmic agent, I)
inefficacy by all four Holter criteria used in this study is
specific and predicts a poor outcome, but 2) efficacy by
Holter criteria is insensitive and does not preclude a poor
outcome.
Efficacy criteria. Holter efficacy criteria I and II in this
study are the same as criteria used by others (1,2) who
reported good predictive values of Holter monitoring in
patients taking amiodarone. Morganroth et al. (7) reported
that, because of spontaneous variability in arrhythmia fre-
quency, only a greater than 83% reduction of ventricular
premature complexes can be attributed to a drug effect at
the 95% confidence level in patients with 30 or more ven-
Figure 3. Arrhythmia-free survival rates by Holter efficacy cri-
terion III (64 patients).
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Table 5. Arrhythmia-Free Survival Rates by the Four Holter Efficacy Criteria
Months
6 12 24 36 P Value*
Holter criterion I
Effective (n = 51) 87% 84% 84% 74%
P = 0.0140Ineffective (n = 23) 72% 61% 61% 31%
Holter criterion II
Effective (n = 44) 80% 74% 74% 74% P = 0.0070Ineffective (n = 7) 57% 43% 43% 0%
Holter criterion III
Effective (n = 51) 89% 86% 86% 76%
P = 0.0000Ineffective (n = 13) 67% 48% 48% 0%
Holter criterion IV
Effective (n = 61) 87% 85% 85% 75%
P = 0.0000Ineffective (n = 12) 58% 39% 39% 0%
*p values by log-rank test.
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only 53% at 12 months and its specificity and positive pre-
dictive value were the lowest. The sensitivity and negative
predictive value of criterion II were the lowest. The sen-
sitivity of criterion III, although one might expect it to be
better in view of a more stringententry criterion, was similar
to that of Holter criteria I and IV. This suggests that, in
patients taking amiodarone, 10 or more ventricular pre-
mature complexes/h at baseline may be adequate for Holter
assessment as compared with 30 or more ventricular pre-
mature complexes/h at baseline (7). Specificity, positive
predictive value and predictive accuracy of Holter criterion
IV were the highest while negative predictive value was
similar to that of other criteria,
Comparison with other studies. Mean loading dose
and maintenance dose of amiodarone in this study and the
timing of Holter monitoring during amiodarone therapy were
similar to those of other studies (1,2). Efficacy rates by
Holter criteria I and II in this study are similar to those of
others (1,2). Marchlinski et al. (I) reported that 34 (62%)
of 55 patients had efficacy by their criterion (Holter criterion
I) as compared with 51 (69%) of 74 patients in our study.
Veltri et al. (2) reported that 34 (81%) of 42 patients had
efficacy by their criterion (Holter criterion II) as compared
with 44 (85%) of 51 in our study.
The results of follow-up of all patients in this study are
somewhat better than those of other studies (1,2) but within
the range of previously reported data (2,15-18). These find-
ings may suggest that our study population and methods are
probably similar to those of other studies.
Morady et al. (4) reported a poor predictive value of
Holtermonitoring of patients on amiodarone therapy, whereas
DiCarloet al. (19) from the same laboratory reported a good
predictive value of Holter monitoring. However, they did
not report the results of Holter monitoring at baseline before
therapy. Many patients (for example, 36% in our study)
have negative results of Holter monitoring at baseline by
their criterion and do not have nonsustained ventricular
tachycardia even before therapy. Because a negative test
after therapy in patients who had a negative test before
Table 7. Predictive Values of the Four Holter Criteria
Holter Efficacy Months
Criteria 6 12 24 36 Total
Table 6. Sensitivity and Specificity of the Four
Holter Criteria Negative predictive value
I 85% 81% 73% 59% 80%
Holter Efficacy Months II 80% 67% 60% 52% 75%
Criteria 6 12 24 36 Total III 88% 83% 75% 62% 82%IV 85% 81% 72% 58% 82%
Sensitivity Positive predictive value
I 50% 53% 53% 50% 47% I 30% 53% 73% 90% 39%
II 30% 29% 29% 29% 31% II 43% 57% 80% 100% 71%
III 44% 50% 50% 47% 44% III 33% 60% 75% 100% 54%
IV 42% 47% 47% 44% 42% IV 42% 70% 88% 100% 67%
Specificity Predictive accuracy
I 70% 81% 86% 93% 75% I 66% 73% 73% 69% 68%
II 86% 87% 94% 100% 94% II 74% 65% 63% 60% 75%
III 81% 88% 90% 100% 88% III 75% 78% 75% 71% 77%
IV 85% 92% 95% 100% 93% IV 76% 79% 76% 69% 79%
Total = entire follow-up period. Total = entire follow-up period.
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therapy may be difficult to interpret, such patients should
probably be excluded in evaluating the value of negative
Holter monitoring during therapy. For this reason we did
not examine their efficacy criterion (4,19). Naccarelli et al.
(5) also reported the values of Holter monitoring in patients
taking amiodarone; however, not every patient in their study
had Holter monitoring at baseline and during amiodarone
therapy.
Limitations of the study. Some patients in our study
received an additional antiarrhythmic agent. Our results might
have been different had we studied patients taking amio-
darone alone. Many investigators (5,20-22), however, are
using an additional antiarrhythmic agent in patients taking
amiodarone, and antiarrhythmic efficacy in these patients is
evaluated by Holter monitoring. For this reason, our study
may be relevant to the clinical management of patients with
ventricular tachycardias.
Conclusions. In patients with refractory ventricular
tachycardia taking amiodarone, alone or in combination with
a class lA agent, we conclude that I) inefficacy by Holter
criteria predicts a poor outcome (specific); 2) efficacy by
Holter criteria, however, does not preclude a poor outcome
(insensitivity); 3) Holter criterion I is the most sensitive,
the least specific with the lowest positive predictive value
and is applicable to 93% of patients; 4) criterion II is the
least sensitive with the lowest negative predictive value and
is applicable to only 64% of patients; 5) criterion III, with
a more stringent entry criterion, is applicable to fewer pa-
tients (80%) than is Holter criterion I or IV, but its sensi-
tivity, specificity, predictive value and predictive accuracy
are not better than those of criteria I and IV; 6) criterion IV
is slightly less sensitive than criterion I but is the most
specific and has the best positive predictive value and pre-
dictive accuracy; 7) criteria I and IV could be applied to
more patients and appear to be better criteria, but their
sensitivity is 53% or less; and 8) further studies should be
done to identify the predictors of recurrence of arrhythmia
in patients with Holter criteria of efficacy.
We express our appreciation to Patti Garcia and Lori Fields for secretarial
assistance in the manuscript preparation.
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